TLL1

Across TCGA pan-cancer cohorts, TLL1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TLL1 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher TLL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TLL1 expression acts as an unfavorable survival marker.

SARC, LUAD, and BLCA are the cancer types where TLL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.122	0.635	<.001	12	view →
LUAD	OS	Median	III,IV	0.145	0.690	<.001	12	view →
BLCA	DFS	Median	All	0.192	0.602	.006	9	view →
OV	DFS	Median	All	0.293	0.543	.009	8	view →
PRAD	DFS	Median	All	0.085	0.774	.002	6	view →
COAD	DFS	Median	III,IV	0.170	0.697	.030	3	view →
SKCM	DFS	Median	All	0.631	0.771	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TLL1–SARC (DFS)

Open the SARC breakdown →